AnaptysBio, Inc.
General ticker "ANAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
AnaptysBio, Inc. follows the US Stock Market performance with the rate: 46.5%.
Estimated limits based on current volatility of 2.0%: low 46.13$, high 48.00$
Factors to consider:
- Total employees count: 104 (-26.8%) as of 2025
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing issues, Market competition, Inability to raise capital
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.62$, 48.54$]
- 2026-12-31 to 2027-12-31 estimated range: [17.36$, 39.88$]
Financial Metrics affecting the ANAB estimates:
- Positive: with PPE of -63.8 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of 2.14 <= 2.37
- Negative: negative Net income
- Positive: 15.80 < Operating profit margin, % of 20.42
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: -0.37 < Inventory ratio change, % of 0
Short-term ANAB quotes
Long-term ANAB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $17.16MM | $91.28MM | $234.60MM |
| Operating Expenses | $181.57MM | $206.23MM | $186.71MM |
| Operating Income | $-164.41MM | $-114.95MM | $47.90MM |
| Non-Operating Income | $0.79MM | $-30.28MM | $-60.96MM |
| R&D Expense | $132.28MM | $163.84MM | $135.97MM |
| Income(Loss) | $-163.62MM | $-145.23MM | $-13.07MM |
| Taxes | $-0.00MM | $0.00MM | $0.16MM |
| Net Income(Loss)* | $-163.62MM | $-145.23MM | $-13.23MM |
| Stockholders Equity | $88.10MM | $70.87MM | $37.21MM |
| Assets | $452.39MM | $483.83MM | $364.39MM |
| Operating Cash Flow | $-120.80MM | $-135.34MM | $19.70MM |
| Capital expenditure | $0.81MM | $0.36MM | $0.09MM |
| Investing Cash Flow | $144.75MM | $95.40MM | $228.03MM |
| Financing Cash Flow | $-59.30MM | $127.05MM | $-132.61MM |
| Earnings Per Share** | $-6.08 | $-5.12 | $-0.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.